Moderna news
The WiseView Research desk's stories that name Moderna, the latest headlines about it, and the trades members of Congress and company insiders have disclosed. The MRNA page →
- HeadlineModerna Jumps 4% Despite William Blair Downgrade on Valuation; Novavax and BioNTech Edge Higher
- HeadlineAxsome Therapeutics vs. Moderna: Consistent Revenue Growth or Sharp Volatility
- HeadlineMerck and Moderna's Cancer Vaccine Worked—Who Gets Paid?
- HeadlineModerna Has Its Doubters. CEO Bancel Plans to Answer With a Cancer Shot.
- HeadlineThe excitement around Moderna's cancer vaccine is cooling. Here's why.
- HeadlineModerna Tumbles 7% as Cancer Vaccine Selloff Deepens; BioNTech Falls 3%, Pfizer Holds Steady
- Pre-market reportPre-Market Report: Futures Rise as Earnings-Heavy Week Begins
Futures climb before the open as traders await a packed earnings week; FICO, EQT and Moderna lead S&P 500 decliners.
- HeadlineModerna, Inc. (MRNA) Discusses Phase III Data for Intismeran and Advances in Cancer Immunotherapy Transcript
- HeadlineModerna Melanoma Therapy Cuts Recurrence Risk 42% in Phase 3 Trial
- HeadlineBreakfast News: A Conversation With Moderna's CEO
- HeadlineHeard on the Street: Moderna's cancer vaccine passed its first big test this past week. The bigger problem is that its stock is priced as if it has already passed them all.
- HeadlineTo the scientific world, Moderna's cancer vaccine's results proved that a highly personalized, immune-targeting medication can work. To investors, it didn't work well enough.
- HeadlineThe real test for Moderna's cancer vaccine isn't about beating Keytruda. It's keeping cancer from coming back in the long term.
- HeadlineModerna leaked data was positive, what's hurting MRNA stock then?
- HeadlineMRNA Tanks as Positive Phase III Cancer Therapy Data Fails to Impress
- HeadlineDoctors call Moderna, Merck's cancer vaccine data a major advancement — even as stocks fall
- HeadlineModerna's Cancer-Vaccine Leak Spurred Panic Selling as Wall Street Wanted a Cure
- HeadlineModerna's Stock Just Stumbled. Is It a Buy on the Dip?
- HeadlineModerna Sinks 4% After 18% Plunge as Melanoma Vaccine Selloff Extends; Merck and Pfizer Slip
- HeadlineModerna Stock Cools After Cancer Vaccine Data Leak
- HeadlineTempus AI: Moderna's New Cancer Vaccine Partner Is The Pick Of The AI Biotech Bunch
- HeadlineModerna Named a Top Employer by Science for Twelfth Consecutive Year
- HeadlineWall Street Breakfast Podcast: Moderna's Good News Goes Bad
- HeadlineModerna stock just crashed 21% in a day; Here's why
- Market closeS&P 500 Falls 1.2%, Nasdaq Sinks 2.6% as Tech Earnings Disappoint
The S&P 500 dropped 1.22% and the Nasdaq slid 2.6% Thursday as tech names sold off, while the Dow eked out a small gain.
- HeadlineModerna Stock Sinks Nearly 20% After Leak of Cancer-Vaccine Data
- HeadlineStock Market Today, Oct. 22: Moderna Stock Plummets 18% on Melanoma Vaccine Data Leak Reports
- HeadlineWhy Moderna stock plunged despite positive cancer vaccine trail results?
- HeadlineModerna sheds about $24 billion as cancer vaccine data triggers 'sell-the-news' retreat
- HeadlineMerck and Moderna Will Present Results From Landmark Phase 3 INTerpath-001 Trial for Intismeran Autogene Plus KEYTRUDA® (pembrolizumab) at ESMO 2026 Presidential Symposium
- HeadlineModerna Stock Crashes 25% After Cancer-Vaccine Data Leak
- HeadlineWhy Is Moderna Stock Sinking Thursday?
- HeadlineModerna shares plunge after leak of partial cancer vaccine data
- HeadlineModerna shares plunged after details from a closely guarded mRNA-based cancer vaccine study were shared on social media
- HeadlineModerna's stock tumbles after reported leak of data for cancer vaccine
- HeadlineModerna Tumbles 25% After Apparent Early Leak of Melanoma Vaccine Data; BioNTech Dips, Pfizer Edges Higher
- HeadlineModerna (MRNA) Rises Higher Than Market: Key Facts
- HeadlineModerna is about to release the trial results for its cancer vaccine. A lot is riding on this data.
- HeadlineModerna's Respiratory Portfolio Expands: Can It Reduce COVID Reliance?
- HeadlineForget COVID: Moderna Is Turning Into a Cancer Company -- and Wall Street Is Taking Notice
- Market closeS&P 500 edges up, Dow jumps 1% as health care and small caps lead
The Dow rose over 1% and the Russell 2000 gained 1.66% as health care stocks led a broad rally, while the Nasdaq slipped slightly.
- HeadlineModerna Jumps 7% While Melanoma Vaccine Data Looms; Bristol Myers Squibb Rises 5%, Pfizer Inches Higher
- HeadlineWhat's Going On With Moderna Stock Monday?
- HeadlineModerna Just Joined the Nasdaq-100. Here's What That Means for Investors.
- HeadlineMove Aside, Moderna: This mRNA Stock Is Sitting on a Cash Pile and a Deep Cancer Pipeline
- HeadlineModerna and Novavax Stocks Slump as Biotech's Rally Takes a Breather
- HeadlineWhy is Moderna down 10% on Friday?
- HeadlineModerna Tumbles 10% as Profit Taking Hits Cancer Vaccine Rally; BioNTech Eases, Pfizer Stays Put
- HeadlineModerna Rallies 6% as Money Rotates Into Healthcare; BioNTech and Pfizer Edge Higher
- HeadlineModerna, Google DeepMind, Biocon on AI in Science
- HeadlineModerna Stock Is Soaring on Cancer Vaccine Buzz. Is It Too Late to Get In?
- HeadlineMRNA Stock Gains Over $4B in a Week: Time to Buy, Hold or Sell?
- HeadlineModerna to Report Third Quarter 2026 Financial Results on Friday, November 6, 2026
- CongressRo Khanna bought $1,001 - $15,000 of MRNA
- CongressRo Khanna bought $1,001 - $15,000 of MRNA
- CongressRo Khanna sold $1,001 - $15,000 of MRNA
- CongressRo Khanna bought $1,001 - $15,000 of MRNA
- CongressRob Bresnahan sold $1,001 - $15,000 of MRNA
- CongressRob Bresnahan bought $1,001 - $15,000 of MRNA
- CongressJulie Johnson sold $1,001 - $15,000 of MRNA
Headlines link to their publishers. Members of Congress disclose ranges, not exact amounts, and may file weeks after the trade; insider filings are open-market purchases and sales from SEC Form 4. For information only, not investment advice.